CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

PURPOSE: CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. PATIENTS AND METHODS: CD33 ex...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Pollard, Jessica A., Loken, Michael, Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Aplenc, Richard, Bernstein, Irwin D., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2016
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872025/
https://ncbi.nlm.nih.gov/pubmed/26786921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.6846
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars